Invion Stock

Invion Equity

The Equity of Invion (IVX.AX) as of Jul 12, 2026.

Equity

0.00AUD

Last updated:

In 2026, Invion's equity was 0.00 AUD, a % increase from the 0.00 AUD equity in the previous year.

Access this data via the Eulerpool API

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Invion's Equity

Invion's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Invion's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Invion's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Invion's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Invion’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Invion stock

On Eulerpool you can find the complete historical development of The Equity Invion since 2006 – with annual values, charts, and detailed analysis.

Access this data via the Eulerpool API

Balance Sheet — Invion

All Key Metrics — Invion